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A B S T R A C T   
Salmonid alphavirus (SAV) is the etiological cause of pancreas disease (PD) in Atlantic salmon (Salmo salar). 
Several vaccines against SAV are in use, but PD still cause significant mortality and concern in European 
aquaculture, raising the need for optimal tools to monitor SAV immunity. To monitor and control the distribution 
of PD in Norway, all salmonid farms are regularly screened for SAV by RT-qPCR. While the direct detection of 
SAV is helpful in the early stages of infection, serological methods could bring additional information on ac-
quired SAV immunity in the later stages. Traditionally, SAV antibodies are monitored in neutralization assays, 
but they are time-consuming and cumbersome, thus alternative assays are warranted. Enzyme-linked immuno-
sorbent assays (ELISAs) have not yet been successfully used for anti-SAV antibody detection in aquaculture. We 
aimed to develop a bead-based immunoassay for SAV-specific antibodies. By using detergent-treated SAV par-
ticles as antigens, we detected SAV-specific antibodies in plasma collected from both a SAV challenge trial and a 
field outbreak of PD. Increased levels of SAV-specific antibodies were seen after most fish had become negative 
for viral RNA. The bead-based assay is time saving compared to virus neutralization assays, and suitable for non- 
lethal testing due to low sample size requirements. We conclude that the bead-based immunoassay for SAV 
antibody detection is a promising diagnostic tool to complement SAV screening in aquaculture.   
1. Introduction 
Salmonid alphavirus (SAV), also named Salmon pancreas disease virus 
(SPDV) by the International Committee on Taxonomy of Viruses, is a 
widespread pathogen in European aquaculture, causing pancreas dis-
ease (PD) and sleeping disease (SD) in Atlantic salmon (Salmo salar) and 
rainbow trout (Oncorhynchus mykiss) respectively. The diseases are 
widespread in Europe and may cause high fish mortality and reduced 
weight gain resulting in decreased fish welfare and great economic 
losses for the industry. The six subtypes of SAV (SAV1-6) are 
geographically separated: SAV1 is common in Ireland and Scotland, 
SAV2 in rainbow trout reared in freshwater in continental Europe [1] as 
well as in salmonids in sea cages in England, Scotland and Norway [2], 
and SAV3 is common in Norway, where the disease has been recognized 
since 1989 [3]. SAV4, 5 and 6 are occasionally detected in the British 
Isles [4]. The subtype classification is based on the nucleotide sequence 
encoding the SAV proteins nsP3 and E2 [5]. There is a general 
cross-neutralization between antibodies produced against all subtypes 
except SAV6, which represents a different serotype [6]. SAV-infected 
fish demonstrate reduced appetite, aberrant swimming, fecal casts and 
lethargy, and the population has increased mortality. Subclinical 
infection can also occur [7]. Histopathological changes, seen as degen-
eration and necrosis, are present in pancreas, heart and skeletal muscle. 
The main route of SAV transmission is horizontal, through virus shed in 
water. The virus can spread between farms via water currents or moving 
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of infected fish, unless proper biosafety measures are implemented 
[8–10]. 
SAV is an enveloped virus with a capped, polyadenylated, single- 
stranded RNA genome with positive polarity. The genome is 11.9 kb 
and consists of two large open reading frames (ORFs). The ORF1 encodes 
four non-structural proteins (nsP1-4), and the ORF2 encodes five 
structural proteins; the capsid, E3, E2, 6K and E1 proteins. The virion 
consists of an icosahedral nucleocapsid that encloses the genome, and a 
surrounding lipid envelope derived from the host cell [11]. The major 
spikes embedded in the lipid envelope consist of trimers of E2 and E1 
glycoprotein heterodimers. Both E1 and E2 are vital for viral entry into 
new cells, with E2 being responsible for receptor recognition and 
binding, and E1 involved in host cell membrane penetration. During 
SAV replication, the non-structural region is translated from the viral 
genomic RNA into a replication complex (RC). The RC replicates the 
viral genome and transcribes the second ORF, which is translated into 
the structural polyprotein capsid-p62-6K-E1. The capsid is cleaved from 
the structural polyprotein and the remaining p62-6K-E1 translocate to 
the endoplasmatic reticulum, where E1 and E2 undergo 
post-translational modifications prior to budding [12]. 
According to the OIE Manual of Diagnostic Tests for Aquatic Animals 
2019, a suspected case of infection with SAV is defined as the presence of 
one of the following: Clinical signs, gross or microscopic pathologic le-
sions consistent with the disease, detection of SAV, detection of anti-
bodies against SAV, or known contact with infected or suspected cases. 
The presence of SAV is confirmed when at least two independent labo-
ratory tests (histopathology, cell culture, RT-qPCR or virus neutraliza-
tion assays) applied on the same individual fish are positive. RT-qPCR is 
well suited for detection of virus in early infection and during clinical 
disease, and currently, all marine production sites in Norway sample 
hearts from 20 fish monthly for RT-qPCR testing [13]. To be at least 95% 
sure to detect at least one SAV-positive fish in 20 random samples, the 
prevalence or infection rate must be at least 15%. 
While serological methods are widely used in terrestrial animals for 
diagnosis, vaccine efficacy studies, surveillance, and the demonstration 
of freedom from disease, the use of such methods have been more 
limited in aquaculture [14]. RT-qPCR will usually be more sensitive at 
peak virus infection, but measurements of serum antibody responses 
may have a diagnostic advantage in the later period of an infection, in 
populations with subclinical infection and low prevalence of infected 
fish, and in cases where SAV RT-qPCR results are on the borderline 
between positive and negative. Neutralizing antibodies are detected in 
SAV infected fish from around two weeks after infection [15,16]. In field 
trials, neutralizing antibodies against SAV have been shown to persist in 
a fish population for as long as 14 months [17]. Virus neutralization 
assays are based on the ability of plasma or serum to inhibit virus 
replication in cell culture after pre-treatment of virus with the samples of 
interest, and are in use for routine diagnostics and to study epidemiology 
in the United Kingdom and Ireland [18–21]. A longitudinal study of two 
outbreaks of PD caused by SAV1, indicated that a neutralization test was 
more sensitive and could detect fish with antibodies against SAV for a 
longer period than RT-qPCR could detect virus [17]. Positive neutrali-
zation tests have also been found at slaughter from fish from farms 
deemed free of SAV through the whole sea water phase by the monthly 
RT-qPCR testing in Norway [22]. However, virus neutralization assays 
require personnel experienced with viral culturing and is time 
consuming, as the incubation time for virus growth in cell culture is at 
least three days [19]. An immunohistochemical method for SAV detec-
tion has been published [23], but could only detect virus in samples 
from the acute stages. Enzyme-linked immunosorbent assays (ELISAs) 
using recombinant E1 or E2 proteins as antigens have been used in 
research to detect antibodies against SAV [24,25], but have not been in 
use for field diagnostics. 
Bead-based immunoassays, such as the xMAP® assay, can be used to 
simultaneously detect antibodies against several pathogens, and we 
have previously used the method to detect antibodies against Piscine 
orthoreovirus (PRV) [26,27]. Such assays have been used to detect an-
tibodies in mammals for almost two decades [28,29]. The analysis can 
be done in a few hours and requires only a few microliters of sample 
material, making the assay suitable to combine with non-lethal sam-
pling. As high background binding and high levels of non-specific an-
tibodies are found in plasma from Atlantic salmon, a functional 
serological assay requires antigens that primarily bind specific anti-
bodies. We have here tested the xMAP method with a bacterially 
expressed recombinant SAV3 E2 protein, whole SAV3 particles and 
disrupted SAV3 particles as antigens. The method was tested on Atlantic 
salmon plasma from an experimental SAV2 and SAV3 infection study 
and field samples from a PD outbreak caused by SAV2. We also 
compared the method with a virus neutralization assay, and with 
RT-qPCR. 
2. Materials and methods 
2.1. Cells 
Chinook salmon embryo cells, (CHSE-214, hereafter referred to as 
CHSE) (RRID:CVCL_2780), were grown at 20 ◦C in Leibovitz (L15) me-
dium supplemented with 10% heat inactivated fetal bovine serum (FBS), 
L-glutamine (2 mM), 2-mercaptoethanol (40 μM) and gentamicin- 
sulphate (50 μg/ml) (all from Life technologies, Paisley, Scotland, UK). 
A transgenic CHSE cell line expressing structural polyprotein of 
SAV1 was generated as follows. The coding sequence for the full poly-
protein from SAV1 isolate 4640 [30] was synthesised by GeneArt® gene 
synthesis service (Thermo Fisher Scientific). Three restriction sites 
(NheI, MluI and XhoI) present in the coding sequence of SAV1-4640 were 
removed by incorporating single nucleotide silent modifications, using 
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μ1c Capsid protein μ1c from PRV virus 
CHH Chum Salmon Heart cells 
CHSE Chinook Salmon Embryo cells 
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NA (Virus) Neutralization Assay 
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PRV Piscine Orthoreovirus 
RC Replication Complex 
SAV Salmonid Alphavirus 
SAV-E1/E2 Glycoproteins E1 or E2 from SAV virus 
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the salmon codon usage, in the sequence data supplied to the DNA 
synthesis company. For the purpose of sub-cloning, MluI, XhoI and 
HindIII, NheI and SalI sites were also added in the synthesised sequence, 
upstream and downstream of the ORF respectively. The resulting 3945 
nucleotide pp4640 coding sequence was sub-cloned into the 
pcDNA3.1-Hyg-mEGFP [31] vector between the sites XhoI and HindIII to 
generate pcDNA3.1-Hyg-mEGFP-pp4640 (ppG). Stable CHSE-ppG 
transfected CHSE cell lines were generated as described previously 
[31]. CHSE-ppG cells were selected and maintained in CHSE culture 
medium supplemented with 30 μg/mL Hygromycin (Invitrogen). 
2.2. Virus propagation 
CHSE-ppG cells were used to propagate the SAV3 H20/03 strain (acc. 
no. DQ149204). The cells were grown in 162 cm2 Costar flasks (Corning 
Incorporated, Corning, NY, USA) for 48 h prior to infection. The medium 
was removed, and cells washed twice with PBS before adding 5 ml virus 
suspension (3 × 107 TCID50/ml) diluted 1:1000 in non-supplemented 
L15 medium and incubated for 1 h at 15 ◦C. This was followed by 
addition of 35 ml L-15 medium supplemented with 2%FBS, 2-mercap-
toethanol (40 μM) and hygromycin (30 μg/ml) and continued incuba-
tion at 15 ◦C for 10 days. Flasks were then transferred directly to − 80 ◦C. 
2.3. Concentration of SAV particles 
SAV particles were concentrated by pelleting, using ultracentrifu-
gation following a protocol developed for the alphavirus Semliki forest 
virus [32], with modifications. The samples were kept on ice throughout 
the entire protocol and cell lysis was performed using the freeze-thaw 
method on ten 162 cm2 flasks containing infected CHSE-ppG and 
non-infected CHSE cells. The lysed cell suspensions were then trans-
ferred to 50 ml centrifuge tubes (Corning Incorporated, Corning, NY, 
USA) and centrifuged at 10,000 g for 20 min at 4 ◦C. The supernatants 
were transferred to five 94 ml polyallomer centrifuge tubes, and the 
tubes sealed with aluminum caps (Beckman-Coulter, Brea, CA, USA). 
Ultracentrifugation was performed at 10,00,00 g for 150 min at 4 ◦C 
using a fixed angle Beckman Type 45 TI rotor in an Optima LE 80 K 
Ultracentrifuge (Beckman-Coulter, Brea, CA, USA). The top aqueous 
phase was removed, and the pellets suspended in 200 μl PBS and incu-
bated overnight at 4 ◦C with 250 rpm rotation. The suspensions were 
pooled together and were then stored at 4 ◦C until further use. 
2.4. RNA extraction and RT-qPCR 
Quantitative real-time PCR was performed to confirm the presence of 
virus and to measure the genome copy number (GCN) ml− 1 in the pooled 
pellets. Extraction of viral RNA was performed using the QIAamp viral 
RNA mini kit (Qiagen, Venlo, Netherlands) following the protocol of the 
manufacturer. Elution of RNA was performed with a 40 μl volume of 
elution buffer from the same kit. The RT-qPCR was performed using the 
Qiagen One-step RT-PCR kit and 3 μl eluted RNA in each reaction. 
Primers and probe, targeting a highly conserved region of the SAV nsp1 
coding sequence, have previously been described [33]. The conditions 
used in each reaction were 400 nM of each primer, 300 nM probe, 0.5 μl 
dNTP mix, 0.32 MgCl, 2.5 μl OneStep RT-PCR buffer, 0.5 μl OneStep 
enzyme mix and 2.3 μl RNase-free water in a total volume of 12.5 μl. For 
the generation of a SAV standard curve, 10-fold dilutions of a plasmid 
containing the complete SAV3 genome, the lowest concentration rep-
resenting one plasmid copy and highest 109 copies, were run in triplicate 
together with the viral samples. The cycling parameters used were 50 
◦C/30 min and 95 ◦C/15 min, followed by 40 cycles of 95 ◦C/15 s, 60 
◦C/1 min on an AriaMx (Agilent, Santa Clara, CA, USA). The presence of 
SAV in the pellet was confirmed with a Ct of 7.5. The standard curve 
slope, regression coefficient and amplification efficiency were − 3.45, 
0.999 and 94.3, respectively (Suppl. Fig. 1). This indicates that the 
standard curve was near optimal and can be used for absolute 
quantitation. By extrapolation we get a GCN of 1.4 × 1011 ml− 1. 
2.5. End-point dilution assay 
The titer of infectious virus per ml (TCID50 ml− 1) in the pelleted virus 
fraction was determined by end-point dilution assay in chum salmon 
heart-1 cells (CHH-1) (RRID:CVCL_4143). Serial 10-fold dilutions were 
made of viral pellet suspension, and 50 μl of each dilution was added in 
eight parallels onto a 96-well plate containing a confluent monolayer. 
The infection protocol was as described above. The plates were incu-
bated for ten days for the appearance of cytopathic effects. CHH-1 cells 
were fixated and stained using an intracellular Fixation and Per-
meabilization buffer (eBioscience, San Diego, CA, USA) and washed in 
Dulbecco’s PBS (DPBS) with sodium azide. Cells were incubated with 
17H23 anti-SAV E2 primary mouse antibody [34] followed by Alexa 
Fluor® 488 anti-mouse secondary antibody from Molecular Probes (Life 
Technologies). Dilutions of primary (1:1000) and secondary (1:400) 
antibodies were performed with permeabilization buffer in accordance 
with the manufacturer’s protocol. For nuclear staining, Hoechst trihy-
drochloride trihydrate (Life Technologies) was used. The number of 
positive wells was quantified using an Olympus IX81 inverted fluores-
cence microscope. The Spearman-Kärber algorithm was used for calcu-
lation of TCID50 ml− 1. The pelleted virus suspension contained 2.0 ×
1010 TCID50 ml− 1. 
2.6. SAV-E2 antigen 
The SAV E2 protein was custom made by the MRC PPU Reagents and 
Services, University of Dundee (https://mrcppureagents.dundee.ac.uk) 
using the following procedure. The full-length E2 coding sequence (acc. 
no. JQ799139), presented in the plasmid pGex-SAV3 E2, was expressed 
as a GST-fusion protein in E. coli (BL21) by induction with isopropyl β-D- 
1-thiogalactopyranoside (IPTG) (50 μM). Bacteria were cultured for 16 h 
before harvesting by centrifugation at 4200×g for 20 min at 4 ◦C. The 
pellet was resuspended in ice cold E. coli lysis buffer (50 mM Tris/HCl 
pH7.5, 250 mM NaCl, 1% Triton-X, 0.1% 2-mercaptoethanol, 1 mM 
Pefabloc (4-(2-aminoethyl)-benzene-sulfonyl fluoride) and 1 mM ben-
zamidine). Bacteria were lysed using a cell disruptor and extracts clar-
ified by centrifugation at 30 000×g for 20 min at 4 ◦C. Proteins were 
then purified using Glutathione S-transferase Agarose using standard 
procedure. Upon elution of the protein with elution buffer (wash buffer 
+ 20 mM glutathione pH 7.5), the fractions containing protein were 
pooled with end over end mixing. This was subjected to purification on a 
HiTrap Heparin Sepharose HP column (GE Healthcare) equilibrated in 
equilibration buffer (50 mM Tris/HCl pH7.5, 0.03% (v/v) Brij 35, 0.1 
mM EGTA, 0.1% 2-mercaptoethanol). A linear salt gradient with 
increasing concentration up to 1 M NaCl was applied to the column and 
SAV E2 containing fractions were pooled and dialyzed into storage 
buffer (50 mM Tris/HCl pH7.5, 150 mM NaCl, 270 mM sucrose, 0.03% 
(v/v) Brij 35, 0.1 mM EGTA, 0.1% 2-mercaptoethanol). The pooled 
protein was incubated for 16 h with GST-PreScission Protease at 4 ◦C 
and a heparin column was used to separate the cleaved GST, GST- 
PreScission Protease and the SAV E2. The expression and protein yield 
were analyzed by SDS PAGE and Coomassie Blue staining. 
2.7. Experimental infection, sample collection and plasma samples 
Plasma from seawater-adapted Atlantic salmon post-smolts was 
collected in a previously published SAV-PRV co-challenge trial [35,36]. 
Only plasma from the SAV-infected control group from the former study 
(not co-infected with PRV) was used in the present work. The fish had 
been challenged as described [35]; briefly, the fish were kept in filtered 
and UV-radiated seawater (34‰ salinity), 12 ◦C (±1 ◦C) and on 24 h 
light. After two weeks, shedder fish were i.p. injected with SAV2 or 
SAV3 (cell culture medium at a concentration of 104 TCID50/ml) and 
introduced to naïve fish four days later. Six cohabitant fish from each 
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SAV subtype infection were sampled at each sampling point (1, 2, 3 and 
6 weeks post challenge (wpc)). Blood was collected from the caudal vein 
on heparinized vacutainer tubes. After centrifugation, plasma was 
collected and stored at − 80 ◦C. Much of the plasma from 6 wpc had been 
used for other purposes, and only two samples from each subtype were 
available for analysis with the xMAP assay. 
As a control for non-specific binding, plasma from a PRV-1 trial 
described in Lund and co-workers [37] was used. These samples had 
previously been used to detect antibodies against PRV [27]. 
The trials were approved by the Norwegian Animal Research Au-
thority and performed in accordance with the recommendations of the 
current animal welfare regulations as outlined in: FOR-1996-01-15-23 
(Norway). 
2.8. Field plasma samples 
The field samples originated from a clinical PD outbreak caused by 
SAV2 in an endemic area (Southern Trøndelag), as described in Røsæg 
and co-workers (pen number 10) [38]. In short, the sampled fish were 
1-year-old smolt of AquaGen strain, vaccinated with Alpha Ject micro 6 
by Pharmaq and sea transferred in July 2014. During the first fall, the 
site was diagnosed with heart and skeletal muscle inflammation (HSMI), 
and the first detection of SAV-RNA from surveillance samples at site 
level was in April 2015. The fish group was then sampled regularly at 
2-3-week intervals from the first SAV-RNA detection until slaughter. 
Clinical PD was first reported in week 27 in 2015 (July 29, 2015), based 
on evaluation from the fish health service, the site manager and a 
coinciding drop in appetite. This was denoted as week 0 of PD. At week 
0 the average fish weight was 2.1 kg, and the cumulative mortality was 
10.7%. At slaughter, the cumulative mortality was 14.35% and the 
average slaughter weight was 4.2 kg. 
The samples included in this study were composed of nine sampling 
points from 3 weeks prior to 15 weeks post the onset of clinical PD. 
Blood samples from ten fish per sampling point were collected in EDTA 
vacuum tubes, kept refrigerated and centrifuged within 24 h. Plasma 
was collected and stored at − 20 ◦C. For detection of SAV-RNA, the heart 
apex was sampled, stabilized in RNAlater® and either held refrigerated 
for 36–48 h before an overnight shipment or frozen below − 20 ◦C prior 
to shipment. The analyses were performed by PatoGen AS according to 
validated and accredited methods (ISO17025 standard). Samples with 
no detection of virus were assigned a Ct of 38 (cut-off value) to include 
them in the graphical presentation. 
2.9. Antigen preparation and coating on beads 
Three different mixtures with whole virus were made from virus 
suspension from CHSE-ppG cells and coated on beads: 1) diluted 1:1 
with PBS (SAV1:1), 2) diluted 1:10 with PBS (SAV1:10), and 3) mixed 
2:1 with 0.1% Triton X-100 (Sigma Aldrich, St. Louis, MO, USA) in PBS 
and kept for 1 h at room temperature before coating (SAV-TX). 
Untransfected and uninfected CHSE cells were used as a background 
control, given that uninfected ppG will still express SAV1 structural 
protein antigens. These were prepared by mixing two parts PBS con-
taining the pellet from CHSE cells with one part PBS containing 0.1% 
Triton X-100 and kept for 1 h at room temperature before coating on 
beads (CHSE control). 60 μl of recombinant E2 protein from SAV3 (0.2 
mg/ml) was used per coupling reaction for beads with E2 (SAV-E2). All 
coating was done according to the producer’s instructions and as pre-
viously described [26,27] using MagPlex® Microspheres (beads) #12, 
#21, #26, #29, # 34, #46 and #64 (Luminex Corp., Austin, TX, USA), 
N-Hydroxysulfosuccinimide sodium salt (Sigma-Aldrich), N-(3-Dime-
thylaminopropyl)-N′-ethylcarbodiimide hydrochloride (Sigma-Aldrich) 
and Bio-Plex Amine Coupling Kit (Bio-Rad, Hercules, CA, USA). PRV μ1c 
and DNP-KLH, a hapten-carrier antigen often used to detect non-specific 
antibodies [39,40], were conjugated to the beads as described earlier 
[26,39]. 
2.10. xMAP assay 
Titrations of plasma was performed, and a 1:50 dilution was found to 
give the best discrimination between control fish and infected fish from 
an experimental challenge trial (data not shown). This dilution was used 
for all samples except for when SAV-E2 and DNP-KLH beads were 
analyzed. Here, a 1:400 dilution was used to stay below the upper limit 
of quantification. As previously described [27], plasma was heated at 48 
◦C for 20 min to minimize non-specific antibody binding. The immu-
noassay was performed as described earlier [26]. In short, plasma was 
diluted 1:50 or 1:400 in PBS and incubated at room temperature for 30 
min on a shaker with the coated beads in a Bio-Plex Pro™ Flat Bottom 
Plate (Bio-Rad). Each sample was incubated with mouse 
Anti-Salmonid-immunoglobulin (Ig) monoclonal antibody (clone 
IPA5F12; Cedarlane, Burlington, Ontario, Canada) (raised against 
salmonid Ig heavy chain, shown to correspond with both identified 
isotypes of Atlantic salmon IgM [41]) diluted 1:400, biotinylated goat 
AntiMouse IgG2a antibody (Southern Biotechnology Association, Bir-
mingham, AL, USA) diluted 1:1000 and finally Streptavidin-PE (Invi-
trogen, Carlsbad, CA, USA) diluted 1:50. Each incubation was performed 
at room temperature on a shaker at 600 rpm for 30 min. Three washings 
were done between each incubation. Control beads were coated with 
proteins from white spot disease virus (ICP11), and from infectious 
salmon anemia virus (FP native and FP-LM), previously described [27]. 
Samples were read using a Bio-Plex 200 (Bio-Rad), with median fluo-
rescence intensity (MFI) as quantitative readout. The results were 
analyzed with the Bio-Plex Manager 6.1 (Bio-Rad). The DD-gate was set 
to 5000–25000, and between 55 and 208 beads from each bead number 
were read from each well. The reading was carried out using a low PMT 
target value. 
2.11. Neutralization assay 
Samples from the field PD outbreak were heat-treated (48 ◦C for 20 
min) and a virus neutralization assay was performed as described earlier 
[19,36] with CHSE cells and acetone fixation before antigen detection 
with immunofluorescence. Endpoint titration of samples was performed 
if virus neutralization was observed at a 1:20 dilution. 
2.12. Statistics 
Statistical analyses used were the Mann-Whitney test to detect sig-
nificant differences in binding to beads, linear regression to examine the 
correlation between MFI from the different beads and Spearman’s cor-
relation to assess the relationship between MFI from beads and 
neutralization data (GraphPad Prism 7 and JMP Pro 14). 
3. Results 
3.1. Virus quantification 
CHSE-ppG cells infected with SAV-3 H20/03 yielded a viral titer of 
3.4 × 109 TCID50/mL, considered high compared to CHSE cells, which 
typically produce a titer of approximately 106 in our laboratory. The 
GCN (1.4 × 1011 ml− 1) for the resuspended virus pellets was approxi-
mately seven-fold higher than those calculated for TCID50 (2.0 × 1010 
ml− 1). A higher GCN ml− 1 is to be expected since this will include RNA 
from virus without considering their infectivity. A real-time PCR assay 
will over-estimate the number of particles since viral RNA-target is also 
detected from free viral RNA from damaged cells and replication in-
termediates. In contrast, a TCID50 assay will under-estimate the amount 
of virus particles since defective virus (non-infectious) are not evaluated. 
We therefore assessed that the number of viral particles in the pellet 
suspension was in between these two estimates (2.0 × 1010–1.4 × 1011). 
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3.2. Assay tested on plasma from fish experimentally challenged with 
SAV 
To assess the xMAP assay for anti-SAV Ig detection under controlled 
conditions, we tested Atlantic salmon plasma from an experimental 
study with SAV2 and SAV3 [35,36]. Plasma was collected from co-
habitants of SAV-injected shedders. At 6 wpc, data showed an increased 
Ig binding (detected as MFI) to beads coated with SAV whole virus 
(SAV1:1), compared to at 1 wpc (Fig. 1a). The beads coated with 1:10 
dilutions of virus (not shown) gave similar results, although slightly 
lower antibody binding for all time points, compared to the 1:1 dilution. 
Beads coated with Triton-X-treated, disrupted SAV particles (SAV-TX) 
showed a significantly higher Ig binding at 2, 3 and 6 wpc compared to 1 
wpc. Beads coated with recombinant SAV-E2 protein showed an 
increased binding to antibodies in plasma samples at 6 wpc, and a wider 
variation between samples at 1, 2 and 3 wpc compared to the other 
beads. Plasma from both SAV2- and SAV3-infected fish bound to all bead 
types in a similar manner. Control beads coated with uninfected CHSE 
cell lysates bound consistently low levels of antibodies in all tested 
plasma, with MFI values below 50 (Fig. 1b). 
A few samples from SAV-injected shedder fish from the same chal-
lenge trial were also tested with the whole virus coated beads and the 
CHSE control beads. Again, the SAV-TX beads showed a higher Ig 
binding compared with SAV1:1 and SAV1:10, rising to an MFI of around 
8000 for some fish, whereas binding to the CHSE control beads was 
consistently low at all time points (Fig. 2). Since both the SAV1:1 and the 
SAV1:10 beads were inferior to the SAV-TX beads, only the latter was 
used for SAV Ig detection in further analyses. 
3.3. Assay tested on plasma from fish experimentally challenged with 
PRV 
To evaluate the specificity of the SAV antigens, the SAV-E2 and SAV- 
Fig. 1. Comparison of Ig binding to xMAP beads coated with SAV antigen. 
A) Comparison between SAV3 E2 protein (SAV-E2), whole SAV3 particles diluted 1:1 (SAV 1:1) and Triton X-100 disrupted SAV3 particles (SAV-TX) coated on xMAP 
beads and used to test plasma from a SAV2/SAV3 cohabitant challenge for SAV-specific antibodies 1, 2, 3 and 6 weeks post challenge (wpc). B) Control beads coated 
with a lysate from the CHSE cells tested on the same plasma samples. MFI with mean values indicated by lines. Significant differences compared to 1 wpc are 
indicated by asterisks (Mann-Whitney test). 
Fig. 2. SAV Ig detection in SAV-3 injected fish. Ig detected in plasma from 
Atlantic salmon injected experimentally (i.p) with SAV3 using an xMAP assay 
with beads coated with whole SAV3 particles (SAV 1:1) and disrupted SAV3 
particles (SAV-TX) as antigen and CHSE control beads. MFI levels with mean. 
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TX were tested on plasma from a PRV challenge trial together with other 
control antigens (Fig. 3). We have previously showed that a PRV 
infection induces production of non-specific, possibly polyreactive an-
tibodies [27], and found high background binding to beads coated with 
the irrelevant antigens: lipid-modified ICP11 protein from shrimp white 
spot syndrome virus (ICP11), lipid-modified infectious salmon anemia 
virus fusion protein (FP-LM) and an unmodified infectious salmon 
anemia virus fusion protein (FP). In contrast to these proteins, the 
SAV-TX beads did not show any binding of non-specific Ig. SAV-E2 
coated beads however, showed a similar background binding pattern 
as the irrelevant antigens. 
3.4. Assay tested on plasma from fish undergoing a PD field outbreak 
To assess the performance of these assays in aquaculture, samples 
from a field PD outbreak were analyzed using SAV-E2, SAV-TX and 
CHSE control beads as well as PRV1-μ1c beads used previously to detect 
PRV specific antibodies [26]. Plasma samples from 3 to 1 weeks before, 
and 2, 4, 6, 8, 10, 13 and 15 weeks after the defined start of the outbreak 
were analyzed. RT-qPCR showed viral RNA presence in fish from week 2 
after the outbreak (Fig. 4a). The binding of plasma antibodies to SAV-TX 
beads started to increase from around two weeks after the PD outbreak, 
except for one fish (of the 10 tested) that was positive in the week before 
the outbreak (Fig. 4b). SAV-TX binding reached a maximum at around 8 
weeks after the outbreak. At 13 and 15 weeks there were still many 
positive fish, while at these time points most of the samples were 
negative for SAV RNA by RT-qPCR (Fig. 4). 
We detected antibodies binding to SAV-E2 beads from all time 
points. There was an increase in mean values from before the outbreak 
to 10 weeks after, similar to what was seen with SAV-TX, but the indi-
vidual variations at each time point were very high (up to >10 000 MFI) 
even before the outbreak (Fig. 4b), and the increase was only statisti-
cally significant in week 10 and 13. 
After the outbreak, all samples except four had neutralizing anti-
bodies and/or virus in plasma (Fig. 5a). The presence of neutralizing 
antibodies could not be determined in viremic samples due to interfer-
ence of the virus with the test principle. Neutralization titers and binding 
to SAV-TX followed roughly the same pattern, with antibody levels 
rising from around two weeks after the outbreak and staying elevated 
until the end of the sampling period, with some individuals deviating 
from this. Strong to moderate correlation between neutralization titers 
and MFI values of SAV-TX and SAV-E2 was found. A Spearman’s cor-
relation shows ρ = 0,73 (p < 0,0001) and ρ = 0,43 (p = 0,0001) for SAV- 
TX (Fig. 5b) and SAV-E2, respectively (Suppl. Fig. 2). There were, 
however, some individuals with high levels of neutralizing antibodies 
and very low levels of binding to SAV-TX and some negative for 
neutralizing antibodies with increased binding to SAV-TX. Weak cor-
relations were found between neutralizing antibodies and binding to the 
other beads in the xMAP analysis (Suppl. Fig. 3). 
Many of the field sample plasma from all time points contained an-
tibodies binding to CHSE control beads. The levels were higher than in 
the challenge trial, but unlike the SAV-E2 and SAV-TX results there were 
no clear increase over this time period (Fig. 6a). A high degree of binding 
was also found to PRVμ1c and DNP-KLH coated beads (Fig. 6b and c). 
By regression analysis, we found a correlation between Ig binding to 
CHSE control beads and SAV-E2 coated beads (Fig. 7). The binding to 
SAV-TX coated beads was not correlated to binding to the CHSE control 
beads (Fig. 7). Binding to DNP-KLH had a low correlation with SAV-E2 
(r2 = 0,21, p > 0,0001) and DNP-KLH beads had lower or no correlation 
with the other beads (Suppl. Fig. 4). 
4. Discussion 
In this study we found that a bead-based immunoassay with dis-
rupted SAV particles was well suited to detect SAV-specific antibodies in 
plasma samples from both experimental infections and field outbreaks. 
Our results show that specific antibodies, covering both subtypes of IgM 
[41], could be detected from between 3 and 6 wpc in cohabitant fish and 
from around 4 wpc in SAV-injected fish. In the field outbreak of PD, a 
significant increase in SAV-specific antibodies was detected from two 
weeks after the defined start of the clinical outbreak. One fish also had 
increased antibody level one week before clinical PD was detected, 
probably reflecting that the virus had been present before infection was 
detected, and that a low prevalence of infected fish may occur for a 
period in the early stages of an outbreak. The level of antibodies in most 
samples remained elevated at the last sample point at 15 weeks after the 
outbreak, when only one sample had a low MFI. At this sampling point 
70% of the samples were SAV negative by RT-qPCR. 
Alphaviruses can be difficult to purify due to the fragility of the 
virion envelope [42]. A study comparing methods of density-gradient 
centrifugation of the alphavirus Semliki forest virus resulted in virus 
recovery of 6–40% [43]. Due to this great loss of virus particles we chose 
direct pelleting by ultracentrifugation as a method of concentration of 
SAV particles rather than purification through a gradient cushion. A 
higher concentration of virus particles was considered of greater 
importance than having a pure sample since the xMAP assay was run 
with a negative control of uninfected CHSE cells also pelleted by ultra-
centrifugation. We used a CHSE cell line (CHSE-ppG), that express the 
Fig. 3. Binding of non-specific Ig to beads coated with irrelevant antigens. Background Ig binding to beads coated with disrupted SAV particles (SAV-TX), 
recombinant E2 protein (SAV-E2) or antigens from other irrelevant viruses measured in plasma from an experimental PRV challenge trial. ICP11: Lipid-modified 
ICP11 protein from shrimp white spot syndrome virus, FP: Infectious salmon anemia virus fusion protein, FP-LM: Lipid-modified FP. MFI levels with mean. 
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SAV-1 structural ORF, due to the missing ability of regular CHSE cells to 
produce large amount of virus when infected with a SAV3 isolate 
(H20/03). These cells are stably transfected with a plasmid that express 
the SAV-1 structural polyprotein with an N-terminal mEFGP tag. It is 
assumed that no viral-like particles are produced by these cells when 
uninfected, most likely because the mEGFP tag will interfere with the 
capsid construction, given that it is approximately the same size as the 
capsid protein (30 kDa). Since the capsid protein is immediately cleaved 
from the structural polyprotein after translation in the cytoplasm, the 
folding and structural conformation of E2 and E1 should not be affected, 
as this takes place in the endoplasmatic reticulum [12]. The limiting 
factors for SAV production in CHSE cells are unknown, but the increased 
access to E1 or E2 could be a positive factor in the production of virus 
particles, and an explanation why the CHSE-ppG produce more virus. 
The CHSE-ppG cells express SAV-1 structural polyprotein while the in-
fectious virus added was a SAV3 subtype and it is not known if the virus 
particles produced in CHSE-ppG were SAV1/3 hybrids. However, due to 
the cross-neutralization between the SAV1-5 subtypes this would 
probably not influence the binding of specific antibodies against SAV3 
or SAV2 [6]. The CHSE-ppG cells were therefore preferred for virus 
propagation to ensure sufficient amount of antigen for the xMAP assay. 
The non-ionic detergent Triton-X was used to disrupt the virus par-
ticles. This method has been used previously to disrupt virus particles for 
bead-based immunoassays [44,45]. Triton-X solubilizes lipid-free 
membrane proteins without disruption of the native structure and bio-
logical function. Triton-X has been found to isolate but not separate E1 
and E2 from the alphavirus Western equine encephalitis virus. The 
capsid was not affected by the treatment [46]. It is therefore likely that 
mainly intact E1-E2 heterodimers as well as virus capsids were present 
on our SAV-TX beads. This likely results in more available antigen on the 
SAV-TX beads compared to beads with untreated whole virus, explain-
ing the increase in binding to SAV-TX compared to untreated SAV. The 
capsid protein may also contribute to the specific antibody binding to 
SAV-TX. Since it is not possible to distinguish which proteins the anti-
bodies bind to, this work should be repeated with beads coated with 
purified recombinant capsid protein. This will show the ability of the 
capsid protein to bind specific antibodies against SAV. 
Furthermore, we tested recombinant SAV-E2 protein as detection 
antigen and found binding of antibodies from experimentally SAV 
infected fish, albeit with a lower signal-to noise ratio. However, it also 
Fig. 4. Analysis of samples from a field outbreak of pancreas disease caused by SAV2. A) SAV RNA levels in hearts. Mean values indicated with lines. B) Levels 
of antibody binding to SAV-TX and SAV-E2 coated beads from plasma from the same outbreak. Mean values indicated with lines. Significant differences compared to 
three weeks before the outbreak are indicated by asterisks (Mann-Whitney test). 
Fig. 5. Virus neutralization assay. A) Titer of neutralizing antibodies from a field PD outbreak. Median values indicated by lines. Neutralizing activity could not be 
determined in samples with viremia (in pink). B) Correlation between antibodies binding to SAV-TX-coated beads and neutralizing titers. NA; Neutralization Assay. 
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came out positive in PRV-infected, SAV-negative fish. The assay also 
gave a high background binding in pre-clinical samples from the PD field 
outbreak. High levels of non-specific, mostly polyreactive antibodies, 
are recognized as an important part of the humoral immune response in 
fish [40,47]. This antibody category may be induced after vaccination 
[39] or by infections [48], including PRV in Atlantic salmon [27]. Fish 
from the PD outbreak had been vaccinated with an inactivated vaccine 
against five bacterial diseases and infectious pancreas necrosis virus. 
Furthermore, these fish were PRV-infected, as they tested positive for 
antibodies against PRV protein μ1c at all time points, and the farm from 
which these fish originated had a diagnosis of HSMI six months prior to 
the first positive SAV sampling. Plasma binding to SAV-E2 correlated 
with binding to CHSE cells, indicating non-specific binding properties. 
However, binding to SAV-E2 did not correlate well with binding to 
DNP-KLH, often used to measure non-specific antibodies [39,40]. Also, 
binding to SAV-E2 increased during the PD outbreak, not seen with 
DNP-KLH or PRV-μ1c beads, indicating that at least a proportion of the 
antibodies binding to SAV-E2 represented SAV-specific binding. A much 
clearer picture emerged with SAV-TX coated beads, which did not result 
in any detectable cross-reactivity when testing plasma from the exper-
imentally PRV-challenged fish, or in the field material prior to PD 
outbreak, despite a high presence of non-specific antibodies in both 
circumstances. This indicates that the SAV-TX antigens primarily bind 
highly specific antibodies against SAV and would be the antigen of 
choice for this immunoassay. 
The non-specific binding to the recombinant E2 protein illustrates a 
pitfall when selecting purified antigens for use in immunoassays for fish. 
The currently used antigen was expressed in a bacterial system, which 
have the disadvantage of growth at 37 ◦C, the lack of glycosylation by 
the bacterial host and aberrant post-translational modification. The E2 
protein has been shown to require co-expression with E1 and lower 
temperatures for correct folding and for translocation and presentation 
on the cell surface [49]. Furthermore, there may be arguments to avoid 
the usage of E2 protein alone. In alphaviruses infecting mammals, an-
tibodies against E2 are more often neutralizing than antibodies binding 
to E1 [50,51]. However, when studying both IgM and IgG produced after 
infection with the alphavirus Chikungunya virus in humans, Chua and 
co-workers found that while neutralizing IgG bound to epitopes on E2, 
neutralizing IgM bound to specific conformation-dependent epitopes on 
the E1-E2 heterodimers [52]. This could also be the case in salmon as 
IgM is the dominating circulating antibody. Experimental SAV vacci-
nation showed that whole structural polyprotein immunization may be 
required to obtain neutralizing antibodies and protection [25]. In 
contrast, a DNA vaccine encoding only the E2 protein provided no an-
tibodies against E2, no neutralizing antibodies, no reduction in pathol-
ogy and no reduction of virus level in serum. In another vaccine 
challenge comparing DNA vaccines and subunit vaccines with E1 or E2 
and an inactivated vaccine, levels of antibodies against E2 did not 
correlate with level of neutralizing antibodies or reduction of mortality 
[24]. Taken together, an intact E1-E2 complex in its native conformation 
may be critical for the detection of specific SAV antibodies that correlate 
with protection. 
SAV neutralization assays can be considered a gold standard for the 
inhibitory effects of SAV-specific antibodies on viral infection [15], and 
a good control for the immunoassay. Despite some discordant in-
dividuals, we found a strong correlation between binding of antibodies 
to SAV-TX beads and neutralization titers. Whereas neutralizing anti-
bodies are expected to target specific epitopes on the SAV E-proteins, the 
SAV-TX beads may also detect antibodies binding to the capsid and any 
part of the E-proteins. In contrast, there was only a moderate correlation 
between SAV-E2-binding and neutralizing antibodies. The binding to the 
SAV-E2 beads are likely a mixture of SAV-specific antibodies against 
linear epitopes and non-specific, possibly polyreactive antibodies. While 
neutralizing antibodies can work in several different ways to block 
infectivity, non-neutralizing antibodies can control infection by 
antibody-dependent cellular toxicity, complement-mediated lysis with 
the formation of a membrane attack complex, and Fc receptor-mediated 
phagocytosis. The relevance of the neutralizing and the specific 
Fig. 6. Binding of plasma from PD outbreak to non-SAV antigens. A) CHSE control beads, B) PRV1-μ1c beads and C) DNP-KLH beads incubated with plasma from 
fish in the PD outbreak. MFI with mean. 
Fig. 7. Correlation between Ig binding to CHSE control and SAV-TX and SAV- 
E2 coated beads. 
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antibodies in relation to protection against PD requires further research. 
To ensure management of PD in Norwegian aquaculture, the Nor-
wegian coastline is divided into different zones by fish health author-
ities, with the aim to control SAV infection in farmed fish. Serological 
methods can have advantages for surveillance in addition to the virus 
screening that is currently performed [14]. Immunoassays may detect 
infection after the peak phase and previous virus encounter longer than 
the virus can be detected in the fish, as shown in this work, and in 
previous studies [17,53]. The xMAP method is time saving compared to 
virus neutralization assays and RT-qPCR. The small amounts of sample 
material needed for xMAP analyses would also make it suitable for 
non-lethal testing and thereby testing of more fish in a surveillance 
program, especially to document freedom from SAV outside of endemic 
zones. Non-lethal sampling for antibodies could be done when the fish 
are handled for lice counting or other procedures. Because of large in-
dividual variations in binding and partly unresolved specificities, sero-
logical testing of salmon for SAV infection should primarily be used for 
groups of fish and not individuals. Plasma from several fish could also be 
pooled. When using pooled samples, more fish can be tested, and the 
distribution of SAV can be better monitored, even when the prevalence 
is low. More testing of the xMAP assay, including on subclinical SAV 
infections, later than 15 weeks after the start of a PD outbreak, with 
pooled samples and on SAV-vaccinated fish, should be done to confirm 
that this method is at least as sensitive and specific as neutralization 
assays. 
Special caution must be taken with serological assays in fish due to 
the relatively high presence of non-specific antibodies. Factors leading 
to high non-specific antibody titers may be a history of vaccination and 
concurring infections; in Norwegian field samples PRV must be expected 
[54,55]. The results presented here demonstrate that a high background 
of non-specific antibodies must be considered when selecting antigens 
and interpreting results. Finding good antigens that bind specifically 
with limited binding to non-specific antibodies is a significant challenge 
for serological tests in Atlantic salmon. The present study indicates that 
Triton-X-treated whole SAV particles may indeed fulfill this goal for SAV 
detection. Further studies to verify the sensitivity and specificity of this 
test system under different practical field situations is warranted before 
employing the method into routine use. 
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